Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

The requested reference [a224c8513430b85d99b2386aafa1256eb7701514] no longer exists in our database. It has been replaced by the current reference: [c1535005781cdfdbaafd8812bfea846ae3029229]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This study will assess the safety, tolerability, and efficacy of every-3-week dosing (Q3W) of pembrolizumab (MK-3475) in participants with advanced melanoma; participants may receive pembrolizumab for up to 2 years if deriving clinical benefit. The primary study hypothesis is that treatment with single agent pembrolizumab will result in a clinically meaningful overall response rate.
Epistemonikos ID: 2249f90c44ff4007dcbd70465388872a8159860f
First added on: May 13, 2020